Compare J B Hunt Transport Services Inc (JBHT) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
J B Hunt Transport Services Inc vs Summit Therapeutics Inc — how do they compare? J B Hunt Transport Services Inc trades at $229.59 (market cap $21.45B), while Summit Therapeutics Inc trades at $17.6 (market cap $13.71B). The key difference: J B Hunt Transport Services Inc is the larger of the two by market cap, and J B Hunt Transport Services Inc pays a 0.79% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold J B Hunt Transport Services Inc for 46 Days and Summit Therapeutics Inc for 16 Days on average.
| JBHT | SMMT | |
|---|---|---|
Market Cap | $21.45B | $13.71B |
Volume | 1,028,680 | 6,173,057 |
Sector | Industrials | Health |
52-Week High | $298.41 | $26.38 |
52-Week Low | $137.09 | $12.43 |
Typical Hold Time | 46 Days | 16 Days |
Enterprise Value | $22.59B | $13.04B |
Dividend Yield | 0.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JBHT trades at $229.26, up 2.97% today, amid a bearish technical signal but strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue has stabilized around $12B, while profitability metrics like ROE (18.45%) and net margin (5.31%) remain solid. However, rising costs and ongoing securities litigation investigations present headwinds.
The outlook is mixed: Wall Street's consensus price target of $289.40 implies significant upside, but near-term pressure from fuel costs and legal overhangs may limit gains. Investors should weigh strong fundamentals against operational risks and market sentiment shifts ahead of Q3 earnings.
Summit Therapeutics (SMMT) trades at $17.59, down 2.01% on the day, amid mixed earnings performance but strong analyst support with a consensus price target of $29.33. The stock shows a bullish technical signal from moving averages, with key support at $17 and resistance at $18. Recent news highlights a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, boosting investor optimism despite current negative profitability metrics.
The outlook for SMMT is heavily driven by clinical progress and partnerships, offering significant upside if drug trials succeed, but carries high risk due to substantial losses, negative cash flow from operations, and reliance on positive trial outcomes. Investors should weigh the potential rewards against the company's current financial health and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About J B Hunt Transport Services Inc
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (45% of sales in 2021).
Read more on JBHT →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
